Is it possible to predict the outcome of the whole lung lavage (WLL) in pulmonary alveolar proteinosis (PAP)?

Ilaria Campo (Pavia, Italy), Ilaria Campo, Michele Zorzetto, Francesco Bonella, Francesca Mariani, Elena Paracchini, Simona Ferrari, Francesca Datturi, Federica Meloni, Maurizio Luisetti

Source: International Congress 2015 – IIPs: orphan
Session: IIPs: orphan
Session type: Thematic Poster Session
Number: 3812
Disease area: Interstitial lung diseases

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Ilaria Campo (Pavia, Italy), Ilaria Campo, Michele Zorzetto, Francesco Bonella, Francesca Mariani, Elena Paracchini, Simona Ferrari, Francesca Datturi, Federica Meloni, Maurizio Luisetti. Is it possible to predict the outcome of the whole lung lavage (WLL) in pulmonary alveolar proteinosis (PAP)?. Eur Respir J 2015; 46: Suppl. 59, 3812

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Whole lung lavage efficacy in pulmonary alveolar proteinosis (PAP) is influenced by the infusion volume?
Source: International Congress 2015 – IIPs: orphan
Year: 2015


Whole lung lavage therapy (WLL) of pulmonary alveolar proteinosis (PAP): A global survey of current practices and procedures
Source: International Congress 2016 – Orphan diseases I
Year: 2016

Early effect of whole lung lavage (WLL) on surfactant homeostasis in pulmonary alveolar proteinosis (PAP)
Source: International Congress 2014 – ILDs: diagnostic and prognostic investigations
Year: 2014



Inhaled sargramostim and whole lung lavage (WLL) as therapy of autoimmune pulmonary alveolar proteinosis (aPAP)
Source: International Congress 2016 – Orphan diseases I
Year: 2016

Inhaled GM-CSF in pulmonary alveolar proteinosis (PAP) patient refractory to plasmapheresis combined with multiple whole lung lavages (WLL)
Source: International Congress 2016 – Orphan diseases I
Year: 2016

Serum biomarkers as prognostic factors of autoimmune pulmonary alveolar proteinosis after whole lung lavage
Source: International Congress 2016 – Orphan diseases I
Year: 2016

Pulmonary alveolar proteinosis (PAP) in exogenous toxic alveolitis (ETA) patients
Source: International Congress 2015 – Occupational disease: clinical cases and series
Year: 2015


Whole lung lavage (WLL) in pulmonary alveolar proteinosis (PAP): long-term lung function follow-up
Source: Eur Respir J 2001; 18: Suppl. 33, 220s
Year: 2001

A gene network to predict the clinical response to whole lung lavage (WLL), in pulmonary alveolar proteinosis (PAP).
Source: International Congress 2017 – Novel and old entities
Year: 2017

Mini-whole lung lavage to treat pulmonary alveolar proteinosis (PAP)
Source: Virtual Congress 2020 – Addressing unresolved questions in rare diffuse parenchymal lung diseases: interdisciplinary research is the key
Year: 2020


Characterization of the gene network driving the whole lung lavage (WLL) outcome in Pulmonary Alveolar Proteinosis (PAP).
Source: International Congress 2018 – Progress in rare interstitial lung diseases
Year: 2018



Whole lung lavage (WLL) for patients with pulmonary alveolar proteinosis
Source: Eur Respir J 2004; 24: Suppl. 48, 670s
Year: 2004

Indication of whole lung lavage in pulmonary alveolar proteinosis – Retrospective study
Source: International Congress 2015 – IIPs: orphan
Year: 2015

Difference in the dynamic state between SP-A and SP-D in the IPF lung
Source: Annual Congress 2013 –Diffuse pulmonary fibrosis
Year: 2013

Pulmonary alveolar proteinosis (PAP) - clinical features and response to treatment by bronchofiberoscopic lobar lavage
Source: Eur Respir J 2005; 26: Suppl. 49, 541s
Year: 2005

What (and how) do we attain by performing surgical lung biopsy for interstitial lung disease?
Source: International Congress 2015 – Interstitial lung diseases II
Year: 2015


Diagnosing Interstitial lung disease. The value of BAL and (cryo)biopsy
Source: ERS Course: Interventional bronchoscopy
Year: 2019

Novel lung function tests in patients with interstitial lung disease (ILD)
Source: International Congress 2016 – Clinical aspects of ILD
Year: 2016

Transbronchial cryobiopsy for the diagnosis of interstitial lung disease (ILD) – The UK experience
Source: International Congress 2015 – IPF: clinical aspects
Year: 2015


Increased apoptosis of alveolar lymphocytes (AL) in idiopathic pulmonary fibrosis (IPF). Potential mechanisms and practical considerations
Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view
Year: 2013